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Abstract: Genetic alterations of leucine-rich repeat kinase 2 (LRRK2), one of the most important
contributors to familial Parkinson’s disease (PD), have been hypothesized to play a role in cancer
development due to demographical and preclinical data. Here, we sought to define the prevalence
and prognostic significance of LRRK2 somatic mutations across all types of human malignancies
by querying the publicly available online genomic database cBioPortal. Ninety-six different studies
with 14,041 cases were included in the analysis, and 761/14,041 (5.4%) showed genetic alterations
in LRRK2. Among these, 585 (76.9%) were point mutations, indels or fusions, 168 (22.1%) were
copy number variations (CNVs), and 8 (1.0%) showed both types of alterations. One case showed
the somatic mutation R1441C. A significant difference in terms of overall survival (OS) was noted
between cases harboring somatic LRRK2 whole deletions, amplifications, and CNV-unaltered cases
(median OS: 20.09, 57.40, and 106.57 months, respectively; p = 0.0008). These results suggest that both
LRRK2 amplifications and whole gene deletions could play a role in cancer development, paving the
way for future research in terms of potential treatment with LRRK2 small molecule inhibitors for
LRRK2-amplified cases.
Keywords: LRRK2; cancer; mutations; CNV; prognostic
1. Introduction
Identification of the PARK8 locus [1] and mutations in the leucine-rich repeat kinase 2 (LRRK2)
gene [2,3], located on chromosome 12 (12q12) in familial cases of Parkinson’s disease (PD), more than
fifteen years ago is considered a game-changing discovery in our knowledge of this yet incurable
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neurodegenerative disorder. Today, single LRRK2 mutations represent one of the most frequently
known genetic determinants of PD [4].
The LRRK2 gene consists of 51 exons, and it encodes a large protein of 2527 amino acids,
retaining two catalytic domains with kinase (MAPKKK domain) and GTPase (ROC, Ras in Complex
domain) function and other protein–protein interaction domains (armadillo-like, leucine-rich repeats,
WD40) [5]. All PD-associated mutations identified until now are single nucleotide substitutions,
the most relevant being G2019S, which accounts for approximately half of LRRK2 mutation in
Caucasian populations, underlying approximately 5% of PD cases of autosomal dominant PD and
approximately 2% of PD cases with no known family history [6–8], and R1441C/G/H. Interestingly,
these mutations cluster in the two aforementioned enzymatic domains. The gene encodes for the
LRRK2 protein, also known as dardarin, which is widely expressed in different tissues, namely the
brain, heart, kidney, and lungs [9], but also in peripheral blood mononuclear cells (PBMCs), including
lymphocytes and monocytes [10].
The physiological role of LRRK2 is still not completely understood, despite the enormous amount
of research conducted on this protein in the last years. LRRK2 has been hypothesized to have a
role in several fundamental cellular processes, primarily autophagy, endocytosis, and mitochondrial
and cytoskeletal function [11–14]. Notably, disruptions in all these processes have been implicated
in the neurodegeneration leading to PD [15–18]. Furthermore, as predictable from the expression
of the protein in PBMCs, LRRK2 alterations have also been implicated in dysfunction of immune
pathways [19]. Interestingly, genome-wide association studies have linked LRRK2 to at least three
chronic inflammatory conditions, namely Crohn’s Disease [20–22], leprosy [23], and tuberculosis [24].
Taken together, current evidence strongly suggests a role of LRRK2 misfunction in the pathogenesis of
PD, possibly mediated by a role in neuroinflammation [25].
Current evidence in the literature may suggest a negative association between certain neurological
diseases like PD or Alzheimer’s disease and cancer [26]. Interestingly, demographical data suggest an
increased incidence of cancer in individuals with a germline G2019S LRRK2 mutation, in particular,
melanoma [27–30]; however, findings are not consistent across all studies [31,32]. Moreover, in vitro
models recently demonstrated that downregulation of LRRK2 suppresses cholangiocarcinoma cell
growth [33] and decreases proliferation of papillary thyroid carcinoma [34]; on the other hand,
overexpression of LRRK2 activates survival and proliferation signals in melanocytes and melanoma
cells [35]. A series of molecular studies have linked the abnormal activity of this protein to autophagic
pathways, inflammation, and mitochondrial dysfunction [11–14,19], but a defined role in cancer
pathogenesis needs yet to be elucidated. Several mechanisms for which LRRK2 could display
a tumor-suppressor function have been described, most notably p53 phosphorylation and p21
induction [36], JNK activation [37], and RCAN1 phosphorylation [38]. In contrast, LRRK2 has also a
potentially oncogenic role in MET signaling activation [39]. Using multigene testing panels, LRRK2
demonstrated a prognostic significance in different types of cancers, including oral squamous cell
carcinomas [40], intrahepatic cholangiocarcinoma [33], non-small-cell lung cancer [41,42], and colon
cancer [43]. Recently, great efforts to develop small molecule inhibitors of LRRK2 have been made,
hoping for a disease-modifying role in the setting of PD [44–47]. If an oncogenic role of LRRK2 is
confirmed, those drugs are of potential use in the field of cancer-targeted therapy as well.
The current study aims to establish the prevalence of LRRK2 point mutations, indels or fusions
(hereby MUTs) and copy-number variations (CNVs) in a large cohort of human malignancies, as well
to investigate the potential prognostic value of such genetic alterations.
2. Materials and Methods
A curated set of 176 non-redundant studies publicly available in the online cancer genomic database
cBioPortal [48–50], comprising 46,595 samples from all types of human malignancies, was initially
screened, assessing whether LRRK2 was profiled across those publications; 96 studies endured the
screening (full list available in Table S1), encompassing 23,796 different samples from all human cancers
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excluding those of the eye, the peripheral nervous system, and the thymus. Cases without both MUTs
and CNVs data were excluded; a total of 14,286 samples from 14,041 patients remained. The dataset
was also queried for MUTs alone, comprising 17,454 patients from 94 studies (2 studies excluded
for not profiling LRRK2 MUTs), and for CNVs alone, comprising 15,183 patients from 93 studies
(3 studies excluded for not profiling LRRK2 CNVs). For survival analysis of the different types of CNVs,
(i.e., amplifications and whole gene deletions), the raw data were downloaded from the cBioPortal
database and processed with MedCalc Statistical Software version 19.1.3 (MedCalc Software, Ostend,
Belgium). Overall survival was calculated using the Kaplan–Meier Estimate; statistical significance
was calculated with a Log-rank Test. Statistical significance of co-occurrence of alterations of LRRK2
and other genes was calculated with Fisher Exact test for p-values and with the Benjamini–Hochberg
procedure for q-values.
3. Results
Among 96 non-redundant studies publicly available in the online cancer genomic database
cBioPortal [48–50], comprising 46,595 samples from all types of human malignancies, the overall
observed prevalence of LRRK2 genetic alterations was 761/14041 (5.4%), with MUTs accounting for
585 cases (76.9%; 426 missense, 155 truncating, 3 inframe indels, 1 fusion) and CNVs accounting for
168 cases (22.1%; 123 amplifications and 45 whole gene deletions); eight cases (1.0%) showed both
MUTs and CNVs (5 missense and amplification, 1 fusion and amplification, 1 missense and whole gene
deletion, 1 inframe indel and amplification), as shown in Figure 1. All these were somatic alterations,
and no germinal LRRK2 mutations were present in the dataset.
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The distribution of missense, truncating, and inframe mutations across the LRRK2 protein is shown
in the lollipop plot in Figure 3. Of note, one case of endometrial carcinoma displayed the missense
mutation R1441C; one case of stomach adenocarcinoma showed the missense mutation G2019D.
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Figure 3. LRRK2 missense, truncating, and inframe mutations in the studies analyzed. A scattered
mutational distribution is evident. The alterations are color-coded as shown in the legend above [48–50].
Overall survival (OS) analysis of all cancer types pooled together demonstrated a worse prognosis
for cases with LRRK2 alterations (207/613 deceased, median OS: 94.03 months) in comparison to
cases with unaltered LRRK2 (4123/11,356 deceased, median OS: 103.26 months) as shown in Figure 4;
this result was statistically significant, with p = 0.0280.
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Figure 4. Overall survi al of LRRK2 altered (MUT and/or CNV) vs. LRRK2 non-altered cas s. A slightly
worse prognosis can be observed for alt red cases [48–50]. MUT: point mutations, indels and fusions;
CNV: copy-number variations.
By stratifying for organ sites, a similar result was observed for prostate adenocarcinoma (LRRK2
altered: 6/16 deceased, median OS months: 120, vs. LRRK non-altered: 127/649 deceased, median
OS: 115.13 months; p = 0.037); interestingly, an opposite, statistically significant trend was noted for
endometrial carcinoma (LRRK2 altered: 6/85 deceased, median OS: NA, vs. LRRK non-altered: 110/479
deceased, median OS: 110.10 months; p = 0.0001481; Figure 5). No other significant results for other
organ sites were noted, with trends pointing toward a better/worse prognosis in different settings
(Figure S1).
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Figure 5. Overal sur K2 altered (MUT and/or CNV) vs. LRRK2 non-altered cases in
prosta ic adenocarcino endometrial carcinoma (B). The pr gno tic significance of LRRK2
altered cases is negative for rostatic cancer and positive for endometrial cancer [48–50]. MUT: point
mutations, indels and fusions; CNV: copy-number variations.
When analyzing M Ts and s alone, a significant (p = 0.0005102) worse survival was noted
within the CNV-altered cases (52/111 deceased, median OS: 55.47 months) in contrast to CNV-unaltered
ones (4799/13198 deceased, mean OS: 106.57 months); no difference was noted in the cohort analyzed
for MUTs only (827/17454; mutated cases: 210/597 deceased, mean OS: 84 months; non-mutated cases:
3711/10945, median OS: 78.8 months; p = 0.870; Figure 6). The majority of CNV-altered cases included in
the survival analysis are composed of LRRK2 amplifications (85 amplifications and 26 deep deletions).
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By stratifying for amplifications and deletions, survival analysis shows a significantly (p = 0.0008)
worse prognosis in terms of OS for whole gene deleted cases (13/26 deceased, median OS: 20.09 months)
in comparison to amplified cases (39/85 deceased, median OS: 57.40 months) and unaltered cases
(4799/13,198 deceased, median OS: 106.57 months; Figure 7).
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Table 1. Co-occurrence of amplifications and whole gene deletions of genes located at 12q12 and LRRK2.
Gene Alteration Altered Group Unaltered Group Log Ratio p-Value q-Value Enriched in
SLC2A13 Amp 99 (57.56%) 26 (0.17%) 8.40 5.76 × 10−183 2.83 × 10−178 Altered group
CNTN1 Amp 95 (55.23%) 32 (0.21%) 8.04 2.10 × 10−170 5.16 × 10−166 Altered group
C12ORF40 Amp 88 (51.16%) 27 (0.18%) 8.18 2.46 × 10−158 4.02 × 10−154 Altered group
ABCD2 Amp 85 (49.42%) 30 (0.20%) 7.98 3.71 × 10−150 4.55 × 10−146 Altered group
KIF21A Amp 84 (48.84%) 35 (0.23%) 7.74 2.61 × 10−145 2.56 × 10−141 Altered group
PDZRN4 Amp 82 (47.67%) 35 (0.23%) 7.70 3.80 × 10−141 3.11 × 10−137 Altered group
MUC19 Amp 74 (43.02%) 21 (0.14%) 8.29 1.52 × 10−132 1.06 × 10−128 Altered group
CPNE8 Amp 82 (47.67%) 132 (0.86%) 5.79 1.09 × 10−110 6.65 × 10−107 Altered group
ALG10B Amp 76 (44.19%) 137 (0.90%) 5.62 5.19 × 10−99 2.83 × 10−95 Altered group
PPHLN1 Amp 63 (36.63%) 54 (0.35%) 6.70 1.25 × 10−95 6.15 × 10−92 Altered group
YAF2 Amp 62 (36.05%) 50 (0.33%) 6.78 4.27 × 10−95 1.91 × 10−91 Altered group
GXYLT1 Amp 60 (34.88%) 45 (0.29%) 6.89 4.42 × 10−93 1.81 × 10−89 Altered group
ZCRB1 Amp 60 (34.88%) 46 (0.30%) 6.86 1.01 × 10−92 3.81 × 10−89 Altered group
PRICKLE1 Amp 61 (35.47%) 53 (0.35%) 6.68 3.28 × 10−92 1.15 × 10−88 Altered group
ADAMTS20 Amp 59 (34.30%) 61 (0.40%) 6.42 4.67 × 10−86 1.53 × 10−82 Altered group
PUS7L Amp 55 (31.98%) 52 (0.34%) 6.55 1.96 × 10−81 6.00 × 10−78 Altered group
IRAK4 Amp 54 (31.40%) 53 (0.35%) 6.50 2.62 × 10−79 7.15 × 10−76 Altered group
TWF1 Amp 53 (30.81%) 57 (0.37%) 6.37 2.42 × 10−76 5.93 × 10−73 Altered group
TMEM117 Amp 54 (31.40%) 82 (0.54%) 5.87 5.64 × 10−72 1.32 × 10−68 Altered group
NELL2 Amp 53 (30.81%) 80 (0.52%) 5.88 1.08 × 10−70 2.40 × 10−67 Altered group
CNTN1 DeepDel 38 (22.09%) 15 (0.10%) 7.81 4.09 × 10−64 8.73 × 10−61 Altered group
DBX2 Amp 44 (25.58%) 62 (0.41%) 5.98 2.37 × 10−59 4.85 × 10−56 Altered group
C12ORF40 DeepDel 31 (18.02%) 5 (0.03%) 9.11 5.82 × 10−57 1.14 × 10−53 Altered group
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Table 1. Cont.
Gene Alteration Altered Group Unaltered Group Log Ratio p-Value q-Value Enriched in
ANO6 Amp 44 (25.58%) 76 (0.50%) 5.68 2.06 × 10−56 3.89 × 10−53 Altered group
SLC2A13 DeepDel 35 (20.35%) 20 (0.13%) 7.28 4.60 × 10−56 8.35 × 10−53 Altered group
KIF21A DeepDel 30 (17.44%) 6 (0.04%) 8.79 3.24 × 10−54 5.67 × 10−51 Altered group
PLEKHA8P1 Amp 41 (23.84%) 66 (0.43%) 5.79 1.86 × 10−53 3.14 × 10−50 Altered group
ABCD2 DeepDel 29 (16.86%) 5 (0.03%) 9.01 5.03 × 10−53 8.23 × 10−50 Altered group
PDZRN4 DeepDel 32 (18.60%) 19 (0.12%) 7.22 6.05 × 10−51 9.57 × 10−48 Altered group
SCAF11 Amp 38 (22.09%) 77 (0.50%) 5.45 1.49 × 10−46 2.08 × 10−43 Altered group
ADAMTS20 DeepDel 31 (18.02%) 26 (0.17%) 6.73 1.57 × 10−46 2.13 × 10−43 Altered group
GXYLT1 DeepDel 28 (16.28%) 13 (0.09%) 7.58 3.17 × 10−46 4.15 × 10−43 Altered group
ARID2 Amp 38 (22.09%) 79 (0.52%) 5.42 3.22 × 10−46 4.15 × 10−43 Altered group
CPNE8 DeepDel 27 (15.70%) 10 (0.07%) 7.91 6.85 × 10−46 8.62 × 10−43 Altered group
ALG10B DeepDel 25 (14.53%) 10 (0.07%) 7.79 4.00 × 10−42 4.90 × 10−39 Altered group
LINC02402 Amp 29 (16.86%) 31 (0.20%) 6.38 1.64 × 10−41 1.96 × 10−38 Altered group
YAF2 DeepDel 26 (15.12%) 16 (0.10%) 7.17 3.27 × 10−41 3.82 × 10−38 Altered group
ZCRB1 DeepDel 25 (14.53%) 12 (0.08%) 7.53 3.96 × 10−41 4.52 × 10−38 Altered group
PPHLN1 DeepDel 25 (14.53%) 14 (0.09%) 7.31 3.17 × 10−40 3.53 × 10−37 Altered group
PRICKLE1 DeepDel 26 (15.12%) 19 (0.12%) 6.93 4.66 × 10−40 5.08 × 10−37 Altered group
PUS7L DeepDel 26 (15.12%) 22 (0.14%) 6.71 5.09 × 10−39 5.43 × 10−36 Altered group
IRAK4 DeepDel 25 (14.53%) 22 (0.14%) 6.66 2.89 × 10−37 2.78 × 10−34 Altered group
NELL2 DeepDel 24 (13.95%) 25 (0.16%) 6.41 1.25 × 10−34 9.57 × 10−32 Altered group
RACGAP1P Amp 27 (15.70%) 47 (0.31%) 5.67 1.65 × 10−34 1.24 × 10−31 Altered group
TWF1 DeepDel 22 (12.79%) 21 (0.14%) 6.54 2.29 × 10−32 1.29 × 10−29 Altered group
MUC19 DeepDel 17 (9.88%) 2 (0.01%) 9.56 4.64 × 10−32 2.50 × 10−29 Altered group
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Table 1. Cont.
Gene Alteration Altered Group Unaltered Group Log Ratio p-Value q-Value Enriched in
SCAF11 DeepDel 24 (13.95%) 36 (0.24%) 5.89 6.43 × 10−32 3.43 × 10−29 Altered group
TMEM117 DeepDel 23 (13.37%) 30 (0.20%) 6.09 1.21 × 10−31 6.27 × 10−29 Altered group
LINC00938 Amp 27 (15.70%) 65 (0.43%) 5.21 1.65 × 10−31 8.34 × 10−29 Altered group
DBX2 DeepDel 21 (12.21%) 21 (0.14%) 6.47 1.20 × 10−30 5.75 × 10−28 Altered group
ARID2 DeepDel 25 (14.53%) 54 (0.35%) 5.36 3.63 × 10−30 1.65 × 10−27 Altered group
PLEKHA8P1 DeepDel 21 (12.21%) 25 (0.16%) 6.22 1.49 × 10−29 6.63 × 10−27 Altered group
ANO6 DeepDel 21 (12.21%) 27 (0.18%) 6.11 4.69 × 10−29 2.00 × 10−26 Altered group
LINC00938 DeepDel 21 (12.21%) 27 (0.18%) 6.11 4.69 × 10−29 2.00 × 10−26 Altered group
RACGAP1P DeepDel 20 (11.63%) 21 (0.14%) 6.40 6.07 × 10−29 2.57 × 10−26 Altered group
LINC02402 DeepDel 10 (5.81%) 7 (0.05%) 6.99 4.09 × 10−16 3.74 × 10−14 Altered group
Table 2. Genes located in 12q12-12q15 for which CNVs are associated with cancer, and correlation with LRRK2 CNVs.
Gene Cytoband Alteration Altered Group Unaltered Group Log Ratio p-Value q-Value Enriched in
MDM2 12q15 Amp 36 (20.93%) 480 (3.14%) 2.74 5.05 × 10−19 7.37 x 10−17 Altered group
MDM2 12q15 DeepDel 1 (0.58%) 4 (0.03%) 4.47 0.0544 0.0963 Altered group
CDK4 12q14.1 Amp 26 (15.12%) 350 (2.29%) 2.72 8.28 × 10−14 5.38 × 10−12 Altered group
ERBB3 12q13.2 Amp 22 (12.79%) 133 (0.87%) 3.88 2.18 × 10−18 2.81 × 10−16 Altered group
ERBB3 12q13.2 DeepDel 9 (5.23%) 14 (0.09%) 5.84 1.52 × 10−12 7.93 × 10−11 Altered group
KMT2D 12q13.12 Amp 11 (6.40%) 38 (0.25%) 4.68 4.77 × 10−12 2.32 × 10−10 Altered group
KMT2D 12q13.12 DeepDel 7 (4.07%) 21 (0.14%) 4.89 1.82 × 10−8 3.28 × 10−7 Altered group
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No significant clustering of LRRK2 CNV-altered versus LRRK2 CNV-unaltered cases was observed
in terms of neoplasm staging (Figure S2). Sex and age at diagnosis distribution for LRRK2 CNV-altered
and LRRK2 CNV-unaltered cases are shown in Figure S3; both results were statistically non-significant
(p > 0.05).
4. Discussion
To our knowledge, this is the first study to assess the prevalence, characteristics, and prognostic
implications of LRRK2 alterations in a large cohort of human malignancies. A significant proportion of
cancers (5%, Figure 1) across the majority of tumor subtypes (Figure 2) harbor MUTs and/or CNVs
of this gene involved in the pathogenesis of PD; however, the role of LRRK2 in cancer development
remains to be elucidated, and the possible driver or passenger role of LRRK2 alterations in cancer
needs yet to be established.
The mutational landscape of LRRK2 in this cohort suggests a passenger role of MUTs, given their
scattered distribution and absence of clustering in specific domains such as Pkinase and Roc (Figure 3).
It is also worth noting that the two most commonly encountered mutations of LRRK2 in PD (and
therefore pathogenic, albeit in a different setting of human disease), i.e., G2019S and R1441C, are seldom
encountered (R1441C: n = 1, G2019S: n = 0, with a case showing a somatic mutation at the same codon:
G2019D). An explanation could be represented by a hypothetical tumor-suppressor role of LRRK2 in
normal cellular development, for which a multitude of different inactivating mutations could result
in a decrease of LRRK2 levels and activity; however, this hypothesis is not supported by previously
published data [33] and our subsequent analysis.
The negative prognostic implications of LRRK2 alterations in the studies analyzed (Figure 4) seem
to suggest, on the other hand, that LRRK2 does not simply represent a bystander during the process of
cancer pathogenesis; the conflicting results for prostate adenocarcinoma and endometrial carcinoma
also seem to indicate a site-specific biological meaning of such alterations. By querying for MUTs and
CNVs alone, the two different Kaplan–Meier plots unravel the negative prognostic role of CNV-altered
cases, while the curves for mutated/nonmutated cases almost completely overlap.
By stratifying for the type of copy-number alteration, in comparison to unaltered cases, both whole
gene deleted cases (CNV = −2) and amplified cases (CNV = 2) show a worse prognosis, the former
being more marked. Notably, LRRK2 amplification has been observed to be of indirect oncogenic
potential in papillary renal cell carcinoma and thyroid carcinomas trough MET signaling [39].
Given the nature of the alterations which confer a negative prognostic value to LRRK2, i.e.,
amplifications and deletions, other genes located within or near the locus 12q12 need to be taken into
account when trying to explain a putative role of LRRK2 in cancer development, since duplications
and deletions can involve large segments of DNA strands. The list of genes located at 12q12 and
their frequency of CNV alterations in LRRK2 CNV-altered and CNV unaltered cases is shown in
Table 1; notably, all genes are significantly co-altered along with LRRK2 (percentage of co-alterations
range: 5.81–57.56%; percentage of alterations in LRRK2 unaltered cases range: 0.07-0.54%; Log
ratio range: 5.21–9.56). By querying the OncoKB database [51,52] for genes located at 12q12, only
ARID2 deletion was found to be likely oncogenic, specifically in non-small cell lung cancer [53] and
hepatocellular carcinoma [54]; in our analysis, ARID2 whole gene deletion co-occurred in 14.53% of
LRRK2 CNV-altered cases.
CNVs of other genes located at 12q12-12q15 are known to be oncogenic, such as KMT2D
deletions [55], ERRB3 amplifications [56], CDK4 amplifications [57], and MDM2 amplifications [58].
Correlations between CNV of those genes and LRRK2 in our analysis are presented in Table 2. Notably,
amplifications of MDM2 and CDK4 are both associated with liposarcoma [57,58]. Given the oncogenic
role of amplification of ERRB3, CDK4, and MDM2, it could be speculated that LRRK2 represents
only a passenger of 12q amplification; it must be noted, though, that the major impact on prognosis
is observed in LRRK2 whole gene deleted cases, and the concordance between LRRK2 and KMT2D
whole gene deletions is 4.07% in our analysis, and a significant proportion of LRRK2-amplified cases
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lack amplification of MDM2, CDK4, and ERBB3. Besides, MDM2 acts as a down-regulator of p53
by initiating its ubiquitination which leads to proteasomal degradation [59], and LRRK2 has been
described to phosphorylate p53 [36], therefore protecting it from MDM2-induced degradation; in this
view, the 20.93% of cases harboring both LRRK2 and MDM2 amplifications could not rely on the latter
as a driver of tumor progression. The same applies to the 15.12% of CKD4-amplified cases, as LRRK2
induces p21, a known CKD4 inhibitor [60], via p53 phosphorylation [36].
The hypothesized role of an increase in kinase activity of LRRK2 in cancer development,
if confirmed via in vitro studies, potentially paves the way for the use of small molecule LRRK2
inhibitors beyond PD: LRRK2-amplificated cases are putative candidates for such treatment. Our
analysis indeed shows that LRRK2 amplification, given its negative prognostic significance, could play
a role in cancer development and may be clinically actionable. And yet, we also note a dismal prognosis
for LRRK2 whole gene deleted cases. In this view, an inhibition of LRRK2 activity could prove to be
more harmful than beneficial. However, when considering that both amplifications (gain of function)
and whole gene deletions (loss of function) of LRRK2 are associated with a worse prognosis in cancer,
it must be acknowledged that the modulation of the kinase activity by LRRK2 small molecule inhibitors
in G2019S-mutated PD patients might lead to a normal kinase function rather than a loss of kinase
activity. However, given the complex interplay between the different domains of LRRK2, an inhibition
of its kinase domain could have pleiotropic effects on the function of the whole protein [61,62]. Further
research is needed, both in vitro and in vivo, in order to better characterize the potential anticancer
effects of LRRK2 small molecule inhibitors.
Our analysis provides insights on the potential biological balancing role of LRRK2, a fact hinted at
by the different biological processes in which this gene is involved. A number of other genes have been
described to possess both oncogenic and tumor-suppressor functions [63]. A subset of these genes
possesses kinase activity (e.g., MAP2K4, MAP3K4, PRKAR1A, PRKCB), similarly to LRRK2. In this
view, any CNV alteration could play a role in the disruption of normal cellular homeostasis which
ultimately leads to cancer. Notably, a small molecule LRRK2 inhibitor, LRRK2-IN-1, demonstrated
activity in colorectal and pancreatic cancer via direct inhibition of DCLK1 [64]; the clinical utility of
such therapeutic agents could also spawn further from LRRK2-overexpressed cases.
5. Conclusions
Herein, we demonstrated that a significant subset of human malignancies shows LRRK2 genetic
alterations. The most frequently encountered mutations in PD, G2019S, and R1441C are almost
nonexistent in sporadic human malignancies. LRRK2 CNV, both amplifications and whole gene
deletions, confer a poorer prognosis in terms of OS in comparison to unaltered cases; the latter cases
show the worse prognosis. In contrast, LRRK2 somatic MUTs show no prognostic significance. These
data support the fact that both LRRK2 overexpression and complete loss-of-function could play a role
in cancer development, and potentially pave the way for future research to investigate the potential
treatment of amplified cases with LRRK2 small molecule inhibitors; the dismal prognosis of LRRK2
whole gene deleted cases also needs further research. In contrast, LRRK2 non-activating MUTs are of
probable passenger significance.
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